Get the Stockscreener App
3.33
10.00%
-0.37
Pre-market:
3.39
0.06
+1.80%
Cadrenal Therapeutics Inc stock is traded at $3.33, with a volume of 67,385.
It is down -10.00% in the last 24 hours and down -34.12% over the past month.
Cadrenal Therapeutics Inc is a late-stage biopharmaceutical company advancing novel therapies for life-threatening immune and thrombotic conditions. Its product candidate, CAD-1005, is a first-in-class selective 12-LOX inhibitor being developed to treat heparin-induced thrombocytopenia (HIT), a deadly immune-mediated thrombotic disorder. The pipeline includes two additional clinical-stage assets: tecarfarin and frunexian. Tecarfarin is an oral vitamin K antagonist (VKA) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Frunexian is a first-in-class, Phase 2-ready intravenous Factor XIa inhibitor designed for acute care settings where contact activation of coagulation by medical devices or artificial surfaces.
See More
Previous Close:
$3.70
Open:
$3.8
24h Volume:
67,385
Relative Volume:
1.13
Market Cap:
$10.25M
Revenue:
-
Net Income/Loss:
$-11.89M
P/E Ratio:
-0.5913
EPS:
-5.6317
Net Cash Flow:
$-10.96M
1W Performance:
-20.90%
1M Performance:
-34.12%
6M Performance:
-72.90%
1Y Performance:
-75.97%
1-Day Range:
$3.265
$4.0296
1-Week Range:
$3.265
$4.37
52-Week Range:
$3.265
$14.64
Cadrenal Therapeutics Inc Stock (CVKD) Company Profile
Name
Cadrenal Therapeutics Inc
Sector
Industry
Phone
904-300-0701
Address
822 A1A NORTH, PONTE VEDRA
Compare CVKD vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CVKD
Cadrenal Therapeutics Inc
|
3.33 | 10.25M | 0 | -11.89M | -10.96M | -5.6317 |
VRTX
Vertex Pharmaceuticals Inc
|
450.46 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
614.98 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
884.20 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
287.80 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
160.06 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cadrenal Therapeutics Inc Stock (CVKD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-23 | Initiated | Noble Capital Markets | Outperform |
Cadrenal Therapeutics Inc Stock (CVKD) Latest News
Cadrenal (CVKD) CEO sells shares under Rule 10b5-1 trading plan - Stock Titan
Cadrenal Therapeutics chairman, CEO Pham sells $70,351 in shares By Investing.com - Investing.com UK
CVKD (NASDAQ: CVKD) Form 144 lists Quang X. Pham sales of common stock - Stock Titan
Cadrenal Therapeutics Advances Multi-Indication Strategy For CAD-1005 And Launches Phase 2a Acute Kidney Injury Clinical Plan - marketscreener.com
Cadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026 - The Manila Times
New trial targets kidney injury after heart surgery in $1B market - Stock Titan
Cadrenal Therapeutics (CVKD) Slips 8% Amid Selling Pressure, Testing Key Support LevelsPut Call Ratio - newsline.com
CVKD Q1 2026 Earnings: Narrower-Than-Expected Loss Provides Temporary ReliefNet Income Trends - newsline.com
CVKD Q1 2026 Earnings: EPS beats estimates despite pre-revenue stageDividend Growth Analysis - newsline.com
Cadrenal Therapeutics CEO Pham sells $93,293 in common stock By Investing.com - Investing.com Nigeria
Cadrenal Therapeutics CEO Pham sells $93,293 in common stock - Investing.com
Cadrenal (NASDAQ: CVKD) CEO sells 22,385 shares but keeps large stake - Stock Titan
CVKD Q1 2026 Earnings: Narrower-Than-Expected Loss as Company Advances Rare Disease PipelineEPS Growth Report - newsline.com
symbol__ Stock Quote Price and Forecast - CNN
Cadrenal Therapeutics CEO Quang Pham sells $36,209 in stock By Investing.com - Investing.com Australia
Cadrenal Therapeutics CEO Quang Pham sells $36,209 in stock - Investing.com
Cadrenal Therapeutics (CVKD) CEO sells 8,285 shares in planned trades - Stock Titan
Cadrenal Therapeutics Announces CFO Transition and Interim Appointment - The Globe and Mail
According to the latest filing with the U.S. Securities and Exchange Commission (SEC), Cadrenal Therapeutics, Inc. has officially appointed Quang X. Pham as the company's interim Chief Financial Officer and interim Chief Accounting Officer. - Bitget
Cadrenal Therapeutics Says Matthew Szot Steps Down As CFOSEC Filing - TradingView
Cadrenal (NASDAQ: CVKD) CFO exits as CEO takes interim finance role - Stock Titan
Cadrenal Therapeutics, Inc. Announces CFO Changes, Effective May 28, 2026 - marketscreener.com
Cadrenal’s CAD-1005, a HIT clot drug, targets $2B market as Phase 3 looms - Stock Titan
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event - marketscreener.com
Cadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 - GlobeNewswire
Cadrenal Therapeutics CEO Pham sells $3,074 in common stock - Investing.com UK
Cadrenal Therapeutics CEO Pham sells $3,074 in common stock By Investing.com - Investing.com South Africa
Cadrenal Therapeutics (CVKD) CEO logs 652-share Rule 10b5-1 stock sale - Stock Titan
CVKD Q1 2026 Earnings: EPS Beat with 37% Surprise; Stock Declines SlightlyReturn On Capital - newsline.com
CVKD Q1 2026 Earnings: Narrower EPS Loss Surprises as Development Pipeline AdvancesEstimate Uncertainty - The Legal Advocate
Cadrenal (CVKD) CEO sells 12,763 shares, retains direct and trust holdings - Stock Titan
Cadrenal Therapeutics Q1 2026 Earnings: Narrowed Loss Surpasses Estimates, Stock Edges HigherEPS Growth Rate - The Legal Advocate
CVKD: CAD-1005 offers a novel, upstream approach to HIT, aiming to improve outcomes and reduce costs - TradingView
CVKD: CAD-1005 targets HIT at its immune root, aiming to transform outcomes and reduce costs - TradingView
CVKD Q1 2026 Earnings: Narrower-than-Expected Loss as Pre-Revenue Biotech Advances PipelineOne-Time Loss Impact - The Legal Advocate
Cadrenal Therapeutics (CVKD) Slides 5.2% as Support Level Comes into FocusHead and Shoulders - newsline.com
Cadrenal Therapeutics (CVKD) Holds Steady, Consolidating Between Support and ResistanceGap Up Stocks - The Legal Advocate
Cadrenal Therapeutics CEO Pham sells $6,628 in company stock By Investing.com - Investing.com India
Cadrenal Therapeutics CEO Pham sells $6,628 in company stock - Investing.com
Cadrenal Therapeutics (CVKD) CEO Quang Pham sells 1,165 shares in pre-planned trade - Stock Titan
Cadrenal Therapeutics (CVKD) Holds Steady Above Support as Traders Eye Resistance at $5.45Risk Reversal - The Legal Advocate
CVKD Q1 2026 Earnings: Narrower Loss Surprises; Clinical Progress MaintainedPre-Announcement Alert - thelegaladvocate.com
CVKD Q1 2026 Earnings: Narrowing Losses and Steady Progress in Clinical PipelineMarket Hype Signals - Newser
CVKD Technical Analysis | Trend, Signals & Chart Patterns | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
CVKD Stock Price, Quote & Chart | CADRENAL THERAPEUTICS INC (NASDAQ:CVKD) - ChartMill
Cadrenal Therapeutics to present at Lytham Partners Spring 2026 Investor Conference on May 28 - Pluang
Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026 - marketscreener.com
Cadrenal Therapeutics Inc Stock (CVKD) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cadrenal Therapeutics Inc Stock (CVKD) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 15 '26 |
Sale |
3.58 |
3,666 |
13,124 |
132,715 |
| Pham Quang X | Chairman, CEO and Interim CFO |
Jun 11 '26 |
Sale |
4.12 |
1,462 |
6,023 |
149,377 |
0.40%
0.29%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):